Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.fatetherapeutics.com
Fate Therapeutics, Inc. News Releases
Get the latest updates from Fate Therapeutics, Inc. News Releases directly as they happen.
Follow now 58 followers
Latest posts
Last updated 8 days ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
8 days ago
SAN DIEGO , May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
11 days ago
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products...
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
26 days ago
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
about 1 month ago
SAN DIEGO , April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
2 months ago
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2 months ago
SAN DIEGO , March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics to Present at Upcoming Investor Conferences
3 months ago
SAN DIEGO , Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3 months ago
SAN DIEGO , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4 months ago
SAN DIEGO , Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
5 months ago
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
5 months ago
SAN DIEGO , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Announces Leadership Transition
5 months ago
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025...